Biological therapy in Crohn's disease

Hospital Medicine

Volumn 64, Issue 12, 2003, Pages 708-712

  Gordon, J N ^a   MacDonald, T T ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOKINE; CYTOKINE ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 2 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; N,N' BIS[3,5 BIS[1 (AMIDINOHYDRAZONO)ETHYL]PHENYL]DECANEDIAMIDE; NATALIZUMAB; ONERCEPT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; HOMING RECEPTOR;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; TREATMENT INDICATION; TREATMENT OUTCOME; CD4+ T LYMPHOCYTE; DRUG ANTAGONISM; IMMUNOLOGY; METHODOLOGY; REVIEW; TH1 CELL;

BIOLOGICAL THERAPY; CD4-POSITIVE T-LYMPHOCYTES; CROHN DISEASE; CYTOKINES; HUMANS; RECEPTORS, LYMPHOCYTE HOMING; TH1 CELLS;

EID: 1342309312     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.12.2361     Document Type: Conference Paper

References (22)

1. Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 17(Suppl 2): 31-7
2. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB (1999) Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117: 1271-7
3. Ghosh S, Goldin E, Gordon FH et al (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32
4. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-9
5. Hommes D, van den Blink B, Plasse T et al (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14
6. Hugot JP, Chamaillard M, Zouali H et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603
7. Lindsay JO, Hodgson HJ (2001) Review article: the immunoregulatory cytokine interleukin-10 - a therapy for Crohn's disease? Aliment Pharmacol Ther 15: 1709-16
8. MacDonald TT, Monteleone G, Pender SL (2000) Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51: 2-9
9. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT (2001) Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-9
10. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 1281-90
11. Ogura Y, Bonen DK, Inohara N et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-6
12. Sandborn WJ, Feagan BG, Hanauer SB et al (2001a) An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330-8
13. Sandborn WJ, Hanauer SB, Katz S et al (2001b) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-94
14. Sands BE, Winston BD, Salzberg B et al (2002) Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16: 399-406
15. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ (1997) CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 40: 320-7
16. Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 331: 1029-35
17. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50: 206-11
18. Tilg H, van Montfrans C, van den Ende A et al (2002) Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50: 191-5
19. van Assche G, Rutgeerts P (2002) Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 8: 291-300
20. van Deventer SJ (2002) Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 50: III47-53
21. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117: 1278-87
22. Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF (2002) Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 168: 411-20